Rakuten Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.56M Buy
14,431
+1,747
+14% +$594K 0.01% 268
2025
Q4
$5.06M Sell
12,684
-18,468
-59% -$8.17M 0.02% 275
2025
Q3
$6.58M Buy
+31,152
New +$12.7M 0.02% 213
2025
Q1
$955K Buy
+3,559
New +$915K ﹤0.01% 501
2024
Q3
$636K Buy
2,314
+575
+33% +$150K ﹤0.01% 411
2024
Q2
$430K Buy
1,739
+653
+60% +$103K ﹤0.01% 413
2024
Q1
$162K Buy
1,086
+996
+1,107% +$166K ﹤0.01% 447
2023
Q4
$17.6K Buy
+90
New +$15.3K ﹤0.01% 433

Other funds holding ALNY

Rakuten Investment Management's ALNY Position: Q1 2026 in Review

Rakuten Investment Management increased its Alnylam Pharmaceuticals (ALNY) stake by 14% in Q1 2026, buying an estimated $594K and bringing the position to 14,431 shares worth $4.56M. The position accounts for 0.01% of the portfolio, ranked #268.

Rakuten Investment Management first reported a position in ALNY in Q4 2023 and has held it in 8 quarters since. The position peaked at $6.58M in Q3 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Rakuten Investment Management held 14,431 shares of Alnylam Pharmaceuticals worth $4.56M as of Q1 2026.
  • Rakuten Investment Management bought 1,747 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $594K.
  • Alnylam Pharmaceuticals made up 0.01% of Rakuten Investment Management's portfolio in Q1 2026, its #268 holding.
  • Rakuten Investment Management first reported a position in Alnylam Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
  • Rakuten Investment Management's Alnylam Pharmaceuticals position peaked at $6.58M in Q3 2025.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Rakuten Investment Management's 13F filing for Q1 2026, filed 12 May 2026.